TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9035660
Drug: Nasal douche
Normalized name: Alkalol Nasal Douche Cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal douche (saline solution)
Study: 9035660
Drug: Hand irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand irrigation (saline solution)
Study: 1820757
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation for 2 weeks
Study: 1820757
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation for 4 weeks
Study: 6366345
Drug: 1% Indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Indomethacin solution, 1 drop 4 times daily for 3 months
Study: 6366345
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 drop 4 times daily for 3 months
Study: 21388398
Drug: Hormones secreted
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormones secreted by the pituitary gland
Study: 17009067
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (4-6 IU/hour for 3-5 days)
Study: 17009067
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion + pioglitazone (15 mg/day)
Study: 17009067
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion without pioglitazone
Study: 2878025
Drug: Changing administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Changing administration sets every 24 h
Study: 2878025
Drug: Changing administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Changing administration sets every 120 h
Study: 27980409
Drug: Vilazodone 40
Normalized name: vilazodone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 40 mg/d
Study: 22842368
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise training (15 weeks, 2 sessions per week of walking and 2 sessions per week of resistance training)
Study: 20566009
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate plus zoledronic acid (4 mg intravenously every 3 months)
Study: 19368963
Drug: Visual Analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual Analog Scale (VAS) score treatment
Study: 9466096
Drug: Metoclopramide 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.4 mg kg‐1
Study: 3335729
Drug: Habit training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit training and oxybutynin (2.5 mg three times daily for 1 week, then 5 mg three times daily for 1 week)
Study: 1974399
Drug: Cetirizine 2.5
Normalized name: Levocetirizine 2.5mg/5mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 2.5 mg
Study: 29621568
Drug: Experimental solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental solution containing NaF/TiF4 (189 ppm Ti+4, 500 ppm F‐, pH 4.4)
Study: 29621568
Drug: Commercial solution
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial solution containing SnCl2/NaF/AmF (800 ppm Sn+2, 500 ppm F‐, pH 4.5, Elmex®/GABA, positive control)
Study: 27697553
Drug: Methamphetamine 15
Normalized name: methamphetamine 15 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine 15 mg
Study: 27697553
Drug: Methamphetamine 30
Normalized name: butabarbital/methamphetamine 30 mg-10 mg ORAL TABLET, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine 30 mg
Study: 27697553
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg + Methamphetamine 15 mg
Study: 27697553
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg + Methamphetamine 30 mg
Study: 27697553
Drug: Buspirone 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 0 mg + Methamphetamine 15 mg
Study: 27697553
Drug: Buspirone 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 0 mg + Methamphetamine 30 mg
Study: 21298840
Drug: Centella asiatica
Normalized name: Centella asiatica
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centella asiatica extract capsule (50 mg of extracted asiaticoside per capsule, 2 capsules after meals, three times a day)
Study: 17682639
Drug: 35% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% potassium nitrate/20% benzocaine/10% tetracaine/aqueous hydroxyethyl cellulose gel
Study: 17682639
Drug: Hydroxyethyl cellulose
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose without active agents
Study: 15692981
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection
Study: 16091398
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection and Physiotherapy
Study: 12401641
Drug: Tandospirone 30
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone 30 mg (T30 group)
Study: 12401641
Drug: Tandospirone 10
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone 10 mg (T10 group)
Study: 10091630
Drug: One piribedil
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One piribedil patch (1 PP)
Study: 10091630
Drug: Two piribedil
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two piribedil patches (2 PP)
Study: 7792499
Drug: Single 400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400-mg dose of caffeine
Study: 7792499
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of caffeine (150 or 300 mg every 6 hours)
Study: 7792499
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (no nap and placebo administered every 6 hours)
Study: 2237331
Drug: Minnesota model
Normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnesota model treatment for alcohol abuse
Study: 2407911
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment for alcohol abuse
Study: 327652
Drug: Subcutaneous bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bethanechol chloride 5 mg
Study: 327652
Drug: Oral bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bethanechol chloride 100 mg
Study: 327652
Drug: Oral bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bethanechol chloride 200 mg
Study: 30860573
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus AKT inhibitor capivasertib
Study: 24408035
Drug: Parenteral ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral ω‐3
Study: 24320057
Drug: Broad-spectrum sunscreen
Normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum sunscreen with anti-inflammatory agents starting on the first day after laser treatment.
Study: 24320057
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side treated with petrolatum ointment only.
Study: 22741251
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate D3 tablets (600 mg, twice a day)
Study: 15204148
Drug: New regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: New regimen of fusidic acid suspension (20 mg/kg divided b.i.d.)
Study: 15204148
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of fusidic acid suspension (50 mg/kg divided t.i.d.)
Study: 14615175
Drug: Silicone breast
Normalized name: Tommee Tippee Silicone Breast Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone breast implants (SBI)
Study: 31797039
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (2 times weekly for 5 weeks)
Study: 31797039
Drug: Consecutive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive treatment (5 times weekly for 2 weeks)
Study: 30409184
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of fructose (supplied in a 2‐L volume of 10% fructose in water) daily for 2 weeks
Study: 28079600
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (4×2.5 mg/kg)
Study: 21978382
Drug: GJS (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day)
Study: 8836914
Drug: Interferon (IFN)‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐alpha therapy
Study: 28317503
Drug: Topiramate (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (maximum dosage 200 mg/day) with brief counseling
Study: 24739538
Drug: 10-mg azilsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg azilsartan
Study: 24739538
Drug: 8-mg candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg candesartan cilexetil
Study: 21551316
Drug: Subcutaneous albinterferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin
Study: 21551316
Drug: Subcutaneous albinterferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks)
Study: 14694241
Drug: Non-sequential regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sequential regimen of Budesonide 1600 microg/day for 2 weeks
Study: 14694241
Drug: Budesonide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (various doses)
Study: 2245968
Drug: Recombinant‐DNA human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant‐DNA human growth hormone treatment
Study: 6999640
Drug: Bicitropeptide (BCP-Compound)
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicitropeptide (BCP-Compound)
Study: 11181380
Drug: SCH27899 (Ziracin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH27899 (Ziracin) 1 mg/kg
Study: 11181380
Drug: SCH27899 (Ziracin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH27899 (Ziracin) 3 mg/kg
Study: 11181380
Drug: SCH27899 (Ziracin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH27899 (Ziracin) 6 mg/kg
Study: 11181380
Drug: SCH27899 (Ziracin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH27899 (Ziracin) 9 mg/kg
Study: 11181380
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of SCH27899
Study: 3069879
Drug: Isocarboxazid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocarboxazid treatment
Study: 30657100
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate and chondroitin sulfate capsules (GS/CS)
Study: 29656600
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide (SFOH) 1.0-3.0 g/day
Study: 27434393
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (SEV) 2.4-14.4 g/day
Study: 24750568
Drug: Pro-AMP cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-AMP cream
Study: 24750568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (emollient cream)
Study: 12472205
Drug: Single heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single heparin administration site
Study: 12472205
Drug: Double site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double site heparin administration
Study: 8647351
Drug: Propranolol (beta-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta-adrenoceptor antagonist)
Study: 8077800
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of phosphocreatine in 200 ml of solvent for 10 days (Group 1)
Study: 180393
Drug: Weekly 5‐fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐fluorouracil, intravenously
Study: 180393
Drug: Daily physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physiologic doses of conjugated estrogens by mouth
Study: 180393
Drug: Weekly 5‐fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐fluorouracil, intravenously + placebo
Study: 31934946
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (n=30)
Study: 31934946
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (n=29)
Study: 31934946
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills and patch (n=36)
Study: 26694694
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (twice weekly for six months)
Study: 25263601
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of botulinum toxin type A
Study: 25263601
Drug: Manual needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual needle placement injection of botulinum toxin type A
Study: 17092978
Drug: Diphenhydramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (75 mg)
Study: 15158296
Drug: Placebo (maltodextrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrine plus aspartame 15 g/day)
Study: 11642081
Drug: lipantil therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipantil therapy for 3 months
Study: 8973788
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg
Study: 2192972
Drug: MK-927 (2%);
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-927 (2%); single drop administered
Study: 2192972
Drug: Pilocarpine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (1% q.d.); single dose administered
Study: 2192972
Drug: MK-927 (2%);
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-927 (2%); single dose administered
Study: 2192972
Drug: Pilocarpine (1%);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (1%); single dose administered
Study: 856702
Drug: Dequalinium chloride
Normalized name: dequalinium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dequalinium chloride lozenges
Study: 856702
Drug: Void lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Void lozenges (Control)
Study: 31884945
Drug: FamPALcare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FamPALcare intervention (5-weekly sessions delivered by community-based nurses)
Study: 28782187
Drug: B-Vitamin therapy
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-Vitamin therapy
Study: 19169898
Drug: Netilmicin with
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin with parenteral nutrition
Study: 19169898
Drug: Netilmicin with
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin with fluid therapy
Study: 17824470
Drug: Isapgol (5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isapgol (5.6 g twice daily) + Atorvastatin (10 mg once daily)
Study: 18991624
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg once daily)
Study: 17824470
Drug: Isapgol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isapgol + Atorvastatin
Study: 11477966
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (three doses at weekly intervals)
Study: 11477966
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (daily over 6 weeks)
Study: 1479050
Drug: Fluoxetine 5
Normalized name: fluoxetine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 5 mg/day
Study: 24150249
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS + Sertraline
Study: 24150249
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS + Sertraline
Study: 9881885
Drug: L. casei
Normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. casei Shirota-fermented milk (100 ml three times daily for 4 weeks)
Study: 9881885
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unfermented milk, 100 ml three times daily for 4 weeks)
Study: 9881885
Drug: L. casei
Normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. casei Shirota-fermented milk
Study: 2507181
Drug: Nalbuphine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (200 micrograms.kg‐1 bolus + 50 micrograms.kg‐1.hr‐1 infusion)
Study: 31771038
Drug: Arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic microfracture technique in combination with autologous bone marrow stem cells transplantation
Study: 26010884
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment strategy using FOLFIRI.3 and gemcitabine (Arm 2)
Study: 19303015
Drug: Sulphasalazine (IKK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (IKK inhibitor)
Study: 19303015
Drug: Losartan (AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (AT1 antagonist)
Study: 15243278
Drug: Once-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly alendronate (ALN) 70 mg
Study: 11061584
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/d for 2 weeks
Study: 8287341
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with a bismuth compound, metronidazole and either amoxicillin or tetracycline
Study: 8287341
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori therapy added to conventional ulcer treatment
Study: 2457074
Drug: Hydromorphone 4
Normalized name: HYDROmorphone 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 4 mg
Study: 2457074
Drug: Butorphanol 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.375 mg
Study: 2457074
Drug: Butorphanol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.75 mg
Study: 2457074
Drug: Butorphanol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1.5 mg
Study: 2457074
Drug: Butorphanol 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 3 mg
Study: 2457074
Drug: Butorphanol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 6 mg
Study: 28536999
Drug: OBV/PTV/r +
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBV/PTV/r + RBV for 16 weeks (treatment-experienced)
Study: 28536999
Drug: OBV/PTV/r +
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBV/PTV/r + RBV for 16 weeks (treatment-experienced, relapsed after interferon therapy)
Study: 21724265
Drug: Sertraline (50mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50mg/day p.o.)
Study: 12019663
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg daily)
Study: 11128665
Drug: Amitriptyline (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75-150 mg daily)
Study: 2869745
Drug: N-propylnorapomorphine (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-propylnorapomorphine (19 mg oral dose)
Study: 2869745
Drug: N-propylnorapomorphine (subchronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-propylnorapomorphine (subchronic dosage schedule)
Study: 31805549
Drug: Topical Dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dorzolamide for one week
Study: 29858000
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 28.8 μg
Study: 29606861
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 14.4 μg
Study: 29858000
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 7.2 μg
Study: 29858000
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 3.6 μg
Study: 29858000
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 1.9 μg
Study: 29858000
Drug: SAL DPI
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL DPI 50 μg